A Phase 1 Study of Blinatumomab in Combination with Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients with Poor Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia (ATLL)

A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL)

A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia

A Randomized Phase II Trial of MLN4924 (Pevonedistat) with Azacitidine Versus Azacitidine in Adult Relapsed or Refractory Acute Myeloid Leukemia

A Phase 1 Study of MLN4924 (Pevonedistat) and Belinostat in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

A Phase 1 Study of M3814 in Combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. A Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

A Phase 1b Study of KRT-232 (AMG-232) in Combination with Decitabine in Acute Myeloid Leukemia

A Phase II Randomized Study of Topotecan/Carboplatin with or Without Veliparib in Advanced Myeloproliferative Disorders and Chronic Myelomonocytic Leukemia (CMML)

A Phase 1b/2 Study of Pinometostat in Combination with Standard Induction Chemotherapy in Newly Diagnosed Acute Myelogenous Leukemia (AML) with MLL Rearrangement

A Randomized Phase II Trial of MLN4924 (Pevonedistat) with Azacitidine Versus Azacitidine in Adult Relapsed or Refractory Myeloid Leukemia

A Phase 1b Study with Expansion Cohort of Escalating Doses of KRT-232 (AMG 232) Administered in Combination with Standard Induction Chemotherapy (Cytarabine and Idarubicin) in Newly Diagnosed Acute Myelogenous Leukemia (AML)

A Phase II Randomized Study of Topotecan/Carboplatin with or Without Veliparib in Advanced Myeloproliferative Disorders and Chronic Myelomonocytic Leukemia (CMML)

A Pilot Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23- Rearranged Acute Myeloid Leukemia

A Phase 1b/2 Study of Pinometostat in Combination with Standard Induction Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with MLL Rearrangement

BLAST MRD AML: 1 - A Randomized Phase 2 Study of the Anti-PD-1 Antibody Pembrolizumab in Combination with Conventional Intensive Chemotherapy as Frontline Therapy in Patients with Acute Myeloid Leukemia

BLAST MRD AML: 2 - A Randomized Phase 2 Study of Venetoclax, Azacitidine, and Pembrolizumab Versus Venetoclax and Azacitidine as First Line Therapy in Older Patients with Acute Myeloid Leukemia Who Are Ineligible or Who Refuse Intensive Chemotherapy

A Pilot Study of Nivolumab in Combination with Decitabine and Venetoclax in TP53-Mutated Acute Myeloid Leukemia

An A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: April 17, 2020